Alto Neuroscience Cash Balance Reaches $177 Million, Prepares for ALTO-207 Pivotal Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy ANRO?
"Alto enters 2026 with a very strong clinical and financial foundation," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "The acquisition of ALTO-207 is a potential game-changer for the millions of patients who fail to respond to current depression therapies. We believe the Lancet-published PAX-D study provides robust, independent validation of our approach, and we are moving ALTO-207 into a potentially pivotal Phase 2b trial with high conviction. Our $177 million cash balance puts us in an excellent position to reach the finish line on four major data readouts, providing shareholders with multiple value-inflection points over the next 2 years."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANRO
Wall Street analysts forecast ANRO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.500
Low
25.00
Averages
35.67
High
50.00
Current: 20.500
Low
25.00
Averages
35.67
High
50.00
About ANRO
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alto Neuroscience Secures $120 Million PIPE Financing for ALTO-207 Development
- Financing Size: Alto Neuroscience has announced a PIPE agreement to raise approximately $120 million, primarily aimed at developing ALTO-207 for treatment-resistant depression, which is expected to significantly enhance the company's R&D capabilities.
- Clinical Trial Plans: The funds will support a Phase 2b study of ALTO-207 expected to start in the first half of 2026, while also preparing for a Phase 3 study set to begin in early 2027, with positive results potentially leading to a New Drug Application submission.
- Funding Utilization: By February 28, 2026, the company's estimated cash and cash equivalents are projected to be around $275 million, providing ample financial backing for subsequent clinical trials and NDA submissions, thereby enhancing market competitiveness.
- Stock Issuance Details: Alto plans to offer 2.9 million shares of common stock at $20 each, along with 3.1 million pre-funded warrants at $19.9999 each, which will be immediately exercisable and have no expiration date, increasing investor participation interest.
See More
Alto Secures $120 Million Financing to Advance ALTO-207 Development
- Significant Financing: Alto Neuroscience successfully raised approximately $120 million through a PIPE financing agreement, which will be utilized for the development of ALTO-207, particularly in a Phase 3 clinical trial for treatment-resistant depression, significantly enhancing the company's competitiveness in the psychiatric drug market.
- Clinical Trial Timeline: The company plans to initiate a Phase 2b study of ALTO-207 in the first half of 2026 and expects to enter Phase 3 trials in early 2027, with this timeline paving the way for a potential New Drug Application, addressing the urgent market need for new therapies.
- Investor Confidence: The financing is led by Commodore Capital and includes participation from multiple biotech investors, reflecting growing market confidence in Alto's precision neuroscience strategy, which is expected to bolster the company's reputation and attractiveness in the industry.
- Clear Use of Proceeds: In addition to supporting the clinical development of ALTO-207, the proceeds will also fund general corporate purposes, with the company estimating cash and cash equivalents to reach approximately $275 million by February 28, 2026, ensuring liquidity for the coming years.
See More
Alto Neuroscience Reports FY EPS Beat and Strong Cash Position
- Earnings Performance: Alto Neuroscience reported a FY GAAP EPS of -$2.19, beating expectations by $0.06, indicating an improvement in financial performance despite still being in a loss position.
- Cash Reserve Increase: As of December 31, 2025, the company had approximately $177 million in cash, cash equivalents, and restricted cash, up from about $169 million as of December 31, 2024, reflecting robust financial management.
- Operational Support Capability: The company expects its cash balance to sustain operations into 2028, providing investor confidence and indicating financial stability for the coming years.
- Market Attention: Alto Neuroscience's financial data has garnered market attention, with Seeking Alpha's Quant Rating offering additional analytical perspectives for investors, potentially influencing future investment decisions.
See More
Alto Acquires ALTO-207 to Address Treatment-Resistant Depression
- Acquisition of ALTO-207: In June 2025, Alto acquired ALTO-207, targeting treatment-resistant depression (TRD) with a combination of a dopamine agonist and an antiemetic, with a pivotal Phase 2b trial expected to start in the first half of 2026, potentially offering new treatment options for millions of patients.
- PAX-D Study Validation: The independent PAX-D study demonstrated an effect size of 0.87 for ALTO-207's core mechanism in TRD patients, significantly surpassing current standard treatments, indicating the drug's potential to transform clinical treatment paradigms.
- Strong Financial Foundation: As of December 31, 2025, Alto reported a cash balance of $177 million, expected to fund operations into 2028 while covering four key data readouts, thereby enhancing investor confidence in the company's future.
- ALTO-101 Fast Track: ALTO-101 received FDA Fast Track designation, with topline data from the Phase 2 proof-of-concept trial anticipated around the end of Q1 2026, further advancing Alto's innovative efforts in the field of psychiatry.
See More
Alto Neuroscience to Participate in Virtual Forum
- Management Participation: Alto Neuroscience's management team will participate in the Stifel 2026 Virtual CNS Forum on March 17, 2026, at 12:00 PM ET, showcasing its innovative advancements in psychiatry, aimed at enhancing the company's visibility and credibility among investors.
- Live Webcast Availability: The presentation will be accessible via a live webcast on Alto's investor relations website, with a replay available afterward, ensuring that investors unable to attend in real-time can still access key information, thereby enhancing transparency and investor relations.
- Precision Psychiatry Platform: Alto's Precision Psychiatry Platform leverages brain biomarkers by analyzing EEG activity, neurocognitive assessments, and wearable data to provide personalized and effective treatment options for psychiatric disorders, demonstrating the company's foresight and technological edge in mental health.
- Diverse Clinical Pipeline: Alto's clinical-stage pipeline includes novel drug candidates targeting depression, schizophrenia, and other mental health conditions, reflecting the company's commitment to developing innovative treatment solutions and potential market opportunities.
See More
Helus Pharma's Psychedelic Drug Achieves Phase 3 Success
- Clinical Trial Breakthrough: Helus Pharma's SPL026 demonstrated significant efficacy in a randomized controlled trial for treatment-resistant depression, with a MADRS score difference of -7.35 (p=0.023) among 34 participants, providing clinical proof-of-concept that could shift regulatory and investor perspectives on psychedelic applications in psychiatry.
- Production Quota Increase: The DEA raised the 2026 psilocybin production quota by 67%, creating larger market opportunities for companies like Helus Pharma and accelerating their research and development efforts in psychedelic therapies.
- Strong Financial Backing: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement of its multi-asset clinical pipeline, particularly for key assets like HLP003 and HLP004.
- Optimistic Future Outlook: HLP003 has shown a 100% response rate and 71% remission rate in two pivotal Phase 3 studies, with topline data expected in Q4 2026, further solidifying Helus Pharma's market position in depression treatment.
See More
Alto Neuroscience Secures $120 Million PIPE Financing for ALTO-207 Development
- Financing Size: Alto Neuroscience has announced a PIPE agreement to raise approximately $120 million, primarily aimed at developing ALTO-207 for treatment-resistant depression, which is expected to significantly enhance the company's R&D capabilities.
- Clinical Trial Plans: The funds will support a Phase 2b study of ALTO-207 expected to start in the first half of 2026, while also preparing for a Phase 3 study set to begin in early 2027, with positive results potentially leading to a New Drug Application submission.
- Funding Utilization: By February 28, 2026, the company's estimated cash and cash equivalents are projected to be around $275 million, providing ample financial backing for subsequent clinical trials and NDA submissions, thereby enhancing market competitiveness.
- Stock Issuance Details: Alto plans to offer 2.9 million shares of common stock at $20 each, along with 3.1 million pre-funded warrants at $19.9999 each, which will be immediately exercisable and have no expiration date, increasing investor participation interest.
See More
Alto Secures $120 Million Financing to Advance ALTO-207 Development
- Significant Financing: Alto Neuroscience successfully raised approximately $120 million through a PIPE financing agreement, which will be utilized for the development of ALTO-207, particularly in a Phase 3 clinical trial for treatment-resistant depression, significantly enhancing the company's competitiveness in the psychiatric drug market.
- Clinical Trial Timeline: The company plans to initiate a Phase 2b study of ALTO-207 in the first half of 2026 and expects to enter Phase 3 trials in early 2027, with this timeline paving the way for a potential New Drug Application, addressing the urgent market need for new therapies.
- Investor Confidence: The financing is led by Commodore Capital and includes participation from multiple biotech investors, reflecting growing market confidence in Alto's precision neuroscience strategy, which is expected to bolster the company's reputation and attractiveness in the industry.
- Clear Use of Proceeds: In addition to supporting the clinical development of ALTO-207, the proceeds will also fund general corporate purposes, with the company estimating cash and cash equivalents to reach approximately $275 million by February 28, 2026, ensuring liquidity for the coming years.
See More
Alto Neuroscience Reports FY EPS Beat and Strong Cash Position
- Earnings Performance: Alto Neuroscience reported a FY GAAP EPS of -$2.19, beating expectations by $0.06, indicating an improvement in financial performance despite still being in a loss position.
- Cash Reserve Increase: As of December 31, 2025, the company had approximately $177 million in cash, cash equivalents, and restricted cash, up from about $169 million as of December 31, 2024, reflecting robust financial management.
- Operational Support Capability: The company expects its cash balance to sustain operations into 2028, providing investor confidence and indicating financial stability for the coming years.
- Market Attention: Alto Neuroscience's financial data has garnered market attention, with Seeking Alpha's Quant Rating offering additional analytical perspectives for investors, potentially influencing future investment decisions.
See More
Alto Acquires ALTO-207 to Address Treatment-Resistant Depression
- Acquisition of ALTO-207: In June 2025, Alto acquired ALTO-207, targeting treatment-resistant depression (TRD) with a combination of a dopamine agonist and an antiemetic, with a pivotal Phase 2b trial expected to start in the first half of 2026, potentially offering new treatment options for millions of patients.
- PAX-D Study Validation: The independent PAX-D study demonstrated an effect size of 0.87 for ALTO-207's core mechanism in TRD patients, significantly surpassing current standard treatments, indicating the drug's potential to transform clinical treatment paradigms.
- Strong Financial Foundation: As of December 31, 2025, Alto reported a cash balance of $177 million, expected to fund operations into 2028 while covering four key data readouts, thereby enhancing investor confidence in the company's future.
- ALTO-101 Fast Track: ALTO-101 received FDA Fast Track designation, with topline data from the Phase 2 proof-of-concept trial anticipated around the end of Q1 2026, further advancing Alto's innovative efforts in the field of psychiatry.
See More
Alto Neuroscience to Participate in Virtual Forum
- Management Participation: Alto Neuroscience's management team will participate in the Stifel 2026 Virtual CNS Forum on March 17, 2026, at 12:00 PM ET, showcasing its innovative advancements in psychiatry, aimed at enhancing the company's visibility and credibility among investors.
- Live Webcast Availability: The presentation will be accessible via a live webcast on Alto's investor relations website, with a replay available afterward, ensuring that investors unable to attend in real-time can still access key information, thereby enhancing transparency and investor relations.
- Precision Psychiatry Platform: Alto's Precision Psychiatry Platform leverages brain biomarkers by analyzing EEG activity, neurocognitive assessments, and wearable data to provide personalized and effective treatment options for psychiatric disorders, demonstrating the company's foresight and technological edge in mental health.
- Diverse Clinical Pipeline: Alto's clinical-stage pipeline includes novel drug candidates targeting depression, schizophrenia, and other mental health conditions, reflecting the company's commitment to developing innovative treatment solutions and potential market opportunities.
See More
Helus Pharma's Psychedelic Drug Achieves Phase 3 Success
- Clinical Trial Breakthrough: Helus Pharma's SPL026 demonstrated significant efficacy in a randomized controlled trial for treatment-resistant depression, with a MADRS score difference of -7.35 (p=0.023) among 34 participants, providing clinical proof-of-concept that could shift regulatory and investor perspectives on psychedelic applications in psychiatry.
- Production Quota Increase: The DEA raised the 2026 psilocybin production quota by 67%, creating larger market opportunities for companies like Helus Pharma and accelerating their research and development efforts in psychedelic therapies.
- Strong Financial Backing: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement of its multi-asset clinical pipeline, particularly for key assets like HLP003 and HLP004.
- Optimistic Future Outlook: HLP003 has shown a 100% response rate and 71% remission rate in two pivotal Phase 3 studies, with topline data expected in Q4 2026, further solidifying Helus Pharma's market position in depression treatment.
See More
